A Phase 1, Randomized, Open-Label, Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability and Food Effect of Various Formulations of RDEA3170
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2016
At a glance
- Drugs Verinurad (Primary)
- Indications Gout; Hyperuricaemia
- Focus Pharmacokinetics
- Sponsors Ardea Biosciences
- 11 Aug 2016 Status changed from active, no longer recruiting to completed.
- 31 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
- 11 Sep 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2015 to 1 Oct 2015.